Neuroepidemiology · 2026
Epidemiology and Treatment of Patients with Essential Tremor: A Retrospective Cohort Analysis in the United Kingdom.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saifee Tabish A, O Apos Neill Keltie, Zhuleku Evi, Ghiani Marco, Dzimitrowicz Natasha, Sabater Javier, Becktepe Jos
Аннотация
INTRODUCTION: Essential tremor (ET) carries a substantial burden and unmet need. Limited real-world evidence exists for the epidemiology, clinical characteristics, and treatment patterns of ET in the UK. We conducted a retrospective cohort study using a large electronic health records database from the UK.
METHODS: Data were obtained from Clinical Practice Research Datalink linked with Hospital Episode Statistics inpatient and outpatient databases from 1 January 2010 to 31 December 2022. Point prevalence and cumulative incidence were assessed, including age- and sex-standardized estimates to the Office for National Statistics mid-year population estimates. In a cohort of newly diagnosed ET patients (1 January 2011-31 March 2020), we evaluated baseline characteristics, clinical features, and treatment patterns. We used descriptive statistics as well as time-to-event analyses (Kaplan-Meier methodology).
RESULTS: Age-sex standardized prevalence ranged from 20.62 to 55.08 per 100,000 persons (2010-2021), peaking at 55.08 in 2019. Age-sex standardized cumulative incidence ranged from 3.85 to 6.81 per 100,000 persons (2011-2021), peaking at 6.81 in 2017. Common comorbidities included hypertension (23.43%), pain disorders (17.12%), and diabetes (15.64%). Most patients (86.07%) received at least one pharmacological therapy: propranolol (68.34%), primidone (27.68%), and gabapentin (22.14%) were most frequently used. Median time from diagnosis to treatment initiation was 0.43 months (95% confidence interval [CI]: 0.36-0.46); median time to discontinuation from start of first therapy was 4.63 months (95% CI: 4.27-5.19); median time to switch was 21.22 months (95% CI: 20.14-22.60).
CONCLUSION: This study provides UK-based evidence on ET epidemiology, clinical features, and treatments. Despite lower epidemiological estimates attributable to the requirement for two confirmed diagnoses - a methodological choice prioritizing diagnostic specificity in a condition that is frequently overdiagnosed - ET burden and unmet needs remain substantial.
METHODS: Data were obtained from Clinical Practice Research Datalink linked with Hospital Episode Statistics inpatient and outpatient databases from 1 January 2010 to 31 December 2022. Point prevalence and cumulative incidence were assessed, including age- and sex-standardized estimates to the Office for National Statistics mid-year population estimates. In a cohort of newly diagnosed ET patients (1 January 2011-31 March 2020), we evaluated baseline characteristics, clinical features, and treatment patterns. We used descriptive statistics as well as time-to-event analyses (Kaplan-Meier methodology).
RESULTS: Age-sex standardized prevalence ranged from 20.62 to 55.08 per 100,000 persons (2010-2021), peaking at 55.08 in 2019. Age-sex standardized cumulative incidence ranged from 3.85 to 6.81 per 100,000 persons (2011-2021), peaking at 6.81 in 2017. Common comorbidities included hypertension (23.43%), pain disorders (17.12%), and diabetes (15.64%). Most patients (86.07%) received at least one pharmacological therapy: propranolol (68.34%), primidone (27.68%), and gabapentin (22.14%) were most frequently used. Median time from diagnosis to treatment initiation was 0.43 months (95% confidence interval [CI]: 0.36-0.46); median time to discontinuation from start of first therapy was 4.63 months (95% CI: 4.27-5.19); median time to switch was 21.22 months (95% CI: 20.14-22.60).
CONCLUSION: This study provides UK-based evidence on ET epidemiology, clinical features, and treatments. Despite lower epidemiological estimates attributable to the requirement for two confirmed diagnoses - a methodological choice prioritizing diagnostic specificity in a condition that is frequently overdiagnosed - ET burden and unmet needs remain substantial.